Hansoh Medical Completes Hundreds of Millions in Series B Funding to Strengthen Leadership in Injection Pen Market

VCBeat has learned that,Recently, Hanerxi Medical(Suzhou Hanerxi Medical Device Development Co., Ltd.), completed the number of 100 million yuan B round of financing, led by Fuzhe Fund, JianchuangCo-led by the Medical Growth Fund, Lishui Fuchu and Herui Venture Capital participated as co-investors.

Hansel’s R&D in the field of pen injectors began in 2012, and in 2014, it established “SuZhouhan Erxi Medical Device Development Co., Ltd.”. In 2015, as a subsidiary of Hybio Pharmaceutical Ji Bio, providing first-generation product design. After years of research and development, Hanerxiof the new generation of products, comparison with global injection pen patents completed GlobalFTO review; it has become one of the few domestic enterprises possessing foundational intellectual property rights for pen injectors and has achieved automated production. industrial transformation, supporting the overseas sales of all domestic pharmaceutical companies. This means that, China Has Completely Broken the Overseas Patent Monopoly on Injection Pens, and Poses a direct challenge to overseas injection pen manufacturers.

With the domestic substitution of drugs packaged in cartridge vials and pre-filled syringes (PFS), particularly insulin and GLP-1 receptor agonists, higher demands are being placed on the supply of injection pens. Currently, most GLP-1 drugs are in Phase III clinical trials or at the stage of regulatory submission, with their mass production driving a concentrated demand for injection pens in 2025. It is foreseeable that, as these drugs reach the market in 2025, the annual demand for injection pens will increase by more than 200 million units, posing a direct challenge to production capacity.

Hansei has currently signed supply agreements with multiple large pharmaceutical companies. Based on this round of financing, Hansei will build Asia’s largest production base for injection pens and drug delivery devices in Liandu District, Lishui City.on-site, implement large-scale fully automated production solutions for manufacturing injection pens ISO11608 Full Product Series, and implement EU CE MDRIIb Quality standards. Phase I plans to build a new production capacity of hundreds of millions of injection pens./thousands of disinfection and sterilization devices and anesthesia devices annually 10,000 setsannual production capacity. Phase II will support the construction of all manufacturing processes for injection pens and other drug delivery devices, including mold design and manufacturing, Multiple manufacturing units, including plastic molding and plastic surface treatment, have further expanded their production capacity. And equipped withEstablish dedicated product lines for multiple large pharmaceutical companies.

With this industrial upgrade, Hanershi will establish multiple global production bases for drug delivery devices, address the supply-side gap in injection pens, reduce their supply costs, and provide comprehensive domestic solutions for high-end drug delivery devices.